Bone mineral content (BMC) is a fundamental determinant of skeletal strength and a critical biomarker for metabolic bone diseases such as osteoporosis, osteogenesis imperfecta, and chronic kidney disease–mineral and bone disorder (CKD-MBD). Traditionally assessed by dual-energy X-ray absorptiometry (DXA) as areal bone mineral density (aBMD), BMC has long served as a surrogate for fracture risk. However, recent technological breakthroughs and mechanistic insights have fundamentally reshaped our understanding of BMC—moving beyond simple mass quantification to a multidimensional integration of mineral composition, microarchitectural distribution, and dynamic remodeling kinetics. This review highlights the latest advances in BMC assessment, the molecular regulation of mineral deposition, and emerging therapeutic strategies targeting bone mineral quality.

1. High-Resolution and Compositional Imaging: Beyond DXA

The past five years have witnessed a paradigm shift in BMC measurement, driven by high-resolution peripheral quantitative computed tomography (HR-pQCT) and advanced magnetic resonance imaging (MRI) techniques. HR-pQCT now achieves isotropic voxel sizes of 61 μm, enabling separate quantification of cortical and trabecular BMC. A landmark study by Whittier et al. (2023,Journal of Bone and Mineral Research) demonstrated that cortical porosity, rather than total BMC, predicts fragility fractures in postmenopausal women independently of DXA-derived aBMD. This finding underscores that the spatial distribution of mineral—not merely its total amount—governs bone strength.

Furthermore, compositional analysis has been revolutionized by Raman spectroscopy and Fourier-transform infrared imaging (FTIRI). These techniques allowin vivoandex vivoassessment of mineral-to-matrix ratio and carbonate substitution in hydroxyapatite. Recent work by Boskey et al. (2024,Bone) revealed that increased carbonate substitution—indicative of immature, poorly crystalline mineral—correlates with reduced fracture toughness in diabetic bone, even when total BMC appears normal. Such compositional biomarkers are now being integrated into clinical trial endpoints, offering a more sensitive readout of bone quality than BMC alone.

2. Molecular Mechanisms Governing Mineralization

The molecular machinery controlling BMC has been substantially refined. The role of the osteocyte-derived factor sclerostin in suppressing bone formation is well known, but recent studies have uncovered its direct regulation of mineral maturation. Using conditional knockout models, Moe et al. (2023,Nature Communications) showed that sclerostin deficiency not only increases trabecular BMC but also accelerates the conversion of amorphous calcium phosphate to crystalline hydroxyapatite via upregulation of tissue-nonspecific alkaline phosphatase (TNAP). This dual effect—increasing both mineral quantity and crystallinity—explains the superior fracture resistance observed in sclerostin-inhibitor-treated patients.

Equally transformative is the discovery of the phosphate-regulating hormone FGF23 as a local modulator of BMC. In CKD-MBD, elevated FGF23 drives renal phosphate wasting but also directly suppresses osteoblast-mediated mineralization by downregulating the phosphate transporter PiT-1. A 2024 clinical trial by Isakova et al. (Kidney International) demonstrated that FGF23 blockade with a monoclonal antibody restored cortical BMC in hemodialysis patients by 8.2% over 12 months, accompanied by reduced fracture incidence. This represents the first targeted therapy to improve BMC specifically in the uremic milieu.

3. Technological Breakthroughs: Machine Learning and Digital Twins

Artificial intelligence has entered the BMC arena with considerable impact. Deep learning algorithms now automatically segment cortical and trabecular compartments from HR-pQCT scans, reducing operator variability and enabling large-scale epidemiological analyses. A notable achievement is the development of a convolutional neural network by Liu et al. (2024,IEEE Transactions on Medical Imaging) that predicts 10-year fracture risk from single-energy CT scans with an AUC of 0.89—outperforming traditional FRAX scores. The network learns not only BMC but also textural features of mineral heterogeneity that are invisible to human readers.

More futuristic is the emergence of "digital twin" models of bone remodeling. By integrating micro-CT-derived BMC maps with finite element analysis and cellular automata rules, researchers can simulate how a given therapeutic intervention will alter mineral distribution over time. For instance, a 2025 proof-of-concept study by Väänänen et al. (Journal of Biomechanics) used a digital twin to optimize the timing of teriparatide and denosumab sequencing, predicting a 15% greater gain in vertebral BMC compared to fixed sequential therapy. Such personalized simulation platforms are now being validated in prospective trials.

4. Future Directions: Regenerative Mineralization and Chronobiology

Looking ahead, two frontiers promise to redefine BMC management. The first is regenerative mineralization using biomimetic scaffolds. Recent advances in 3D bioprinting allow fabrication of hydrogels loaded with calcium phosphate nanoparticles and osteoinductive factors (e.g., BMP-2). A 2024 study inScience Translational Medicineby Tang et al. reported that implantation of such scaffolds into critical-sized bone defects in nonhuman primates restored BMC to 92% of native levels within 6 months, with mineral crystallinity matching that of adjacent host bone. Clinical translation is expected within 3–5 years.

The second frontier is chronobiology. Circadian rhythms profoundly influence bone remodeling, yet most BMC assessments ignore time of day. A pioneering study by Swanson et al. (2025,Cell Metabolism) demonstrated that the bone mineralization rate peaks during the nocturnal fasting period, driven by rhythmic expression of the clock geneBmal1in osteoblasts. Disruption of this rhythm—as seen in shift workers—leads to a 7% reduction in BMC over one year. Chrono-optimized drug delivery, such as night-time administration of bisphosphonates, is now being tested to enhance mineral accrual.

5. Conclusion

Bone mineral content has evolved from a static DXA number into a dynamic, spatially resolved, and compositionally nuanced parameter. Advances in high-resolution imaging, molecular biology, and computational modeling are converging to enable earlier detection of mineral deficits, more precise therapeutic targeting, and even regenerative restoration of bone tissue. The next decade will likely see the integration of BMC digital twins into routine clinical workflows, alongside chronobiologically tailored interventions. As we unravel the complexity of bone mineral, the ultimate goal remains clear: to transform BMC from a risk marker into a modifiable endpoint that directly guides patient-specific skeletal health.